ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company’s product includes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; and suPARnostic Quick Triage kit for use in the point of care situation for early warning and patient triaging that allows clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression, and outcome. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.
Metrics to compare | VIROG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIROGPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.5x | −6.1x | −0.5x | |
PEG Ratio | −0.30 | −0.28 | 0.00 | |
Price/Book | 14.7x | 8.6x | 2.6x | |
Price / LTM Sales | 7.5x | 6.8x | 3.3x | |
Upside (Analyst Target) | - | 96.9% | 38.9% | |
Fair Value Upside | Unlock | 6.5% | 5.4% | Unlock |